0001493152-23-039945.txt : 20231108 0001493152-23-039945.hdr.sgml : 20231108 20231108171432 ACCESSION NUMBER: 0001493152-23-039945 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231108 DATE AS OF CHANGE: 20231108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERPACE BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001054102 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 222919486 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24249 FILM NUMBER: 231389240 BUSINESS ADDRESS: STREET 1: WATERVIEW PLAZA, SUITE 310 STREET 2: 2001 ROUTE 46 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 412-224-6100 MAIL ADDRESS: STREET 1: WATERVIEW PLAZA, SUITE 310 STREET 2: 2001 ROUTE 46 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Interpace Diagnostics Group, Inc. DATE OF NAME CHANGE: 20151223 FORMER COMPANY: FORMER CONFORMED NAME: PDI INC DATE OF NAME CHANGE: 20021113 FORMER COMPANY: FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC DATE OF NAME CHANGE: 19980129 8-K 1 form8-k.htm
false 0001054102 0001054102 2023-11-08 2023-11-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 8, 2023

 

INTERPACE BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

 

delaware   0-24249   22-2919486

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Waterview Plaza, Suite 310

2001 Route 46,

Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

 

(855) 776-6419

Registrant’s telephone number, including area code

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☐ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 8, 2023, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the quarter ended September 30, 2023. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference.

 

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
     
99.1   Press Release, dated November 8, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Interpace Biosciences, Inc.
     
  By: /s/ Thomas W. Burnell
  Name: Thomas W. Burnell
  Title: President and Chief Executive Officer

 

Date: November 8, 2023

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results

 

  ● Q3 Revenue of $9.1 million; an 11% increase year-over-year
     
  ● Q3 Test volume up 11% year-over-year
     
  ● Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and collection initiatives

 

PARSIPPANY, NJ, November 8, 2023 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update.

 

Third quarter Net Revenue was $9.1 million, a $0.9 million increase over third quarter 2022. Loss from continuing operations in the third quarter of 2023 was $0.5 million, an improvement of $0.7 million from the prior-year quarter’s loss of $1.3 million. On an adjusted basis, EDITDA was $0.4 million in Q3 and $2.9 million for YTD 2023. Net of previously reported one-time charges, YTD adjusted EBITDA is $3.9 million vs a YTD 2022 loss of $1.8 million.

 

Q3 represented the 3rd consecutive quarter of double-digit volume and revenue growth in 2023 compared to 2022, according to Chris McCarthy, Chief Financial Officer. Tom Burnell, President and CEO, added, “in part due to expansion of test utilization by physicians, the execution of new and re-negotiated commercial contracts, as well as overall price improvement, the cash position of the Company allowed for the full re-payment of $2.5 million that was outstanding on the Company’s Line of Credit with Comerica Bank.” Additionally, Burnell said, “in an effort to continue to improve the Company’s balance sheet, we fully satisfied the $3 million Terminal Payment owed to BroadOak Capital Partners as part of our long-term debt agreement.” The Company was also able to re-negotiate the terms of the LTD, significantly reducing the cost of capital. Finally, Burnell added, “the resiliency of our team is second-to-none. They have endured restructuring, reimbursement challenges, and the shedding of non-performing assets all while optimizing operational efficiency and overall growth of superior molecular diagnostics for assessing the risk of pancreatic and thyroid cancers.” The Company announced that it expects full-year 2023 revenue to exceed $40 million.

 

Third Quarter and 2023 Financial Performance

 

For the Third Quarter of 2023 as Compared to the Third Quarter of 2022

 

  ● Net Revenue was $9.1 million, an increase of 11% from $8.2 million for the prior-year quarter
     
  ● Gross Profit percentage was 55% compared to 58% for the prior-year quarter
     
  ● Operating loss was $(0.02) million vs an operating loss of $(0.8) million in the prior-year quarter
     
  ● A loss from continuing operations was $(0.5) million vs a loss from continuing operations of $(1.3) million in the prior-year quarter
     
  ● Adjusted EBITDA was $0.4 million vs $0.1 million in the prior-year quarter
     
  ● Q3 2023 cash collections totaled $9.8 million vs $7.6 million for Q3 2022
     
  ● September 30, 2023 cash balance of $5.0 million      

 

   

 

 

For the Nine Months Ended September 30, 2023 as Compared to the Nine Months Ended September 30, 2022

 

  ● Net Revenue was $29.9 million, an increase of 27% from $23.5 million for the prior year
     
  ● Gross Profit percentage was 59% compared to 56% for the prior-year quarter, and improved 5% vs 2022     
     
  ● Income from continuing operations was $0.3 million vs a loss from continuing operations of $(4.5) million in the prior year
     
  ● Adjusted EBITDA was $2.9 million vs $(1.8) million loss in the prior year

 

About Interpace Biosciences

 

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

 

Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has five commercialized molecular tests and one test in a clinical evaluation program (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA®, a “molecular only” version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay; ThyraMIR®v2, used in combination with ThyGeNEXT®, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification; and RespriDX®, that differentiates lung cancer of primary versus metastatic origin. In addition, BarreGEN®, a molecular-based assay that helps resolve the risk of progression of Barrett’s Esophagus to esophageal cancer, is currently in a CEP, whereby we gather information from physicians using BarreGEN to assist us in gathering clinical evidence relative to the safety and performance of the test and also providing data that will potentially support payer reimbursement.

 

For more information, please visit Interpace Biosciences’ website at www.interpace.com.

 

Forward-looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the reimbursement of the Company’s tests being subject to review by CMS, the Company’s ability to continue to perform, bill and receive reimbursement for our PancraGEN® molecular test under the existing local coverage determination (“LCD”), given that such LCD is currently under review by Novitas Solutions, Inc., the Company’s Medicare administrative contractor, the possibility that the Company’s estimates of future revenue, cash flows and adjusted EBITDA may prove to be materially inaccurate, the Company’s history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s ability to repay borrowings with Comerica Bank and BroadOak, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect, and the possible removal of the Company’s common stock from trading on the OTCQX®.

 

Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as amended, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

Contacts:

 

Investor Relations

Interpace Biosciences, Inc.

(855)-776-6419

Info@Interpace.com

 

   

 

 

INTERPACE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited, in thousands, except per share data)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
                 
Revenue, net  $9,078   $8,189   $29,931   $23,506 
Cost of revenue   4,124    3,457    12,163    10,286 
Gross Profit   4,954    4,732    17,768    13,220 
                     
Sales and marketing   2,498    2,236    7,444    6,987 
Research and development   149    191    484    626 
General and administrative   2,124    2,767    7,515    8,636 
Acquisition amortization expense   199    318    834    953 
Change in fair value of contingent consideration   -    -    -    (311)
Total operating expenses   4,970    5,512    16,277    16,891 
                     
Operating (loss) income   (16)   (780)   1,491    (3,671)
Interest accretion expense   (26)   (38)   (92)   (123)
Note payable interest   (230)   (230)   (682)   (620)
Other expense, net   (252)   (217)   (408)   (20)
(Loss) income from continuing operations before tax   (524)   (1,265)   309    (4,434)
Provision (benefit) for income taxes   4    (11)   12    24 
(Loss) income from continuing operations   (528)   (1,254)   297    (4,458)
                     
Loss from discontinued operations, net of tax   (86)   (12,954)   (385)   (15,936)
                     
Net loss  $(614)  $(14,208)  $(88)  $(20,394)
                     
Basic (loss) income per share of common stock:                    
From continuing operations  $(0.12)  $(0.30)  $0.07   $(1.05)
From discontinued operations   (0.02)   (3.05)   (0.09)   (3.77)
Net loss per basic share of common stock  $(0.14)  $(3.35)  $(0.02)  $(4.82)
                     
Diluted (loss) income per share of common stock:                    
From continuing operations  $(0.12)  $(0.30)  $0.07   $(1.05)
From discontinued operations   (0.02)   (3.05)   (0.09)   (3.77)
Net loss per diluted share of common stock  $(0.14)  $(3.35)  $(0.02)  $(4.82)
                     
Weighted average number of common shares and
common share equivalents outstanding:		  
 		  
 		  
 		  
 		  
 		  
 		  
 		  
 		  
 		  
 		  
 		  
 		  
 		  
 		  
 		  
 
Basic   4,319    4,242    4,313    4,227 
Diluted   4,319    4,242    4,355    4,227 

 

   

 

 

Selected Balance Sheet Data (Unaudited)

($ in thousands)

 

   September 30, 2023   December 31, 2022 
Cash and cash equivalents  $5,032   $4,828 
           
Total current assets   11,438    12,154 
Total current liabilities   12,324    14,283 
           
Total assets   14,250    15,979 
Total liabilities   30,394    32,515 
Total stockholders’ deficit   (62,680)   (63,072)

 

Selected Cash Flow Data (Unaudited)

($ in thousands)

 

   For the Nine Months Ended 
   September 30, 
   2023   2022 
Net loss  $(88)  $(20,394)
           
Net cash provided (used in) operating activities  $2,649   $(7,416)
Net cash provided by investing activities   55    7,305 
Net cash (used in) provided by financing activities   (2,500)   3,106 
Change in cash, cash equivalents and restricted cash   204    2,995 
Cash, cash equivalents and restricted cash – beginning   4,828    3,314 
Cash, cash equivalents and restricted cash – ending  $5,032   $6,309 

 

Reconciliation of Adjusted EBITDA (Unaudited)

($ in thousands)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
(Loss) income from continuing operations (GAAP Basis)  $(528)  $(1,254)  $297   $(4,458)
Depreciation and amortization   241    353    954    1,076 
Stock-based compensation   152    501    501    1,110 
Tax expense (benefit)   4    (11)   12    24 
Interest accretion expense   26    38    92    123 
Note payable interest   230    230    682    620 
Mark to market on warrant liability   -    (3)   -    (71)
Change in fair value of note payable   259    206    400    46 
Change in fair value of contingent consideration   -    -    -    (311)
Adjusted EBITDA  $384   $60   $2,938   $(1,841)

 

Non-GAAP Financial Measures

 

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.

 

In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock based compensation and ESPP plans, interest and taxes, and other non-cash expenses including change in fair values of notes payable, contingent consideration and warrant liability. The table above includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

 

   

 

 EX-101.SCH 3 idxg-20231108.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 idxg-20231108_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 idxg-20231108_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 08, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 08, 2023
Entity File Number 0-24249
Entity Registrant Name INTERPACE BIOSCIENCES, INC.
Entity Central Index Key 0001054102
Entity Tax Identification Number 22-2919486
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One Waterview Plaza
Entity Address, Address Line Two Suite 310
Entity Address, Address Line Three 2001 Route 46
Entity Address, City or Town Parsippany
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07054
City Area Code (855)
Local Phone Number 776-6419
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001054102 2023-11-08 2023-11-08 iso4217:USD shares iso4217:USD shares false 0001054102 8-K 2023-11-08 INTERPACE BIOSCIENCES, INC. DE 0-24249 22-2919486 Waterview Plaza Suite 310 2001 Route 46 Parsippany NJ 07054 (855) 776-6419 false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://interpace.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm idxg-20231108.xsd idxg-20231108_lab.xml idxg-20231108_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "IDXG", "nsuri": "http://interpace.com/20231108", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "idxg-20231108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "idxg-20231108_lab.xml" ] }, "presentationLink": { "local": [ "idxg-20231108_pre.xml" ] } }, "keyStandard": 21, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 21 }, "report": { "R1": { "role": "http://interpace.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://interpace.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-23-039945-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-039945-xbrl.zip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